TP53 and cancer: R175H is the most common mutation found in human cancer that impairs DNA-binding and ATM-mediated DNA-damage-response, thereby leading to genetic instability and defective G2/M checkpoint control.50 Further analyses on how this TP53/FOXO3-complex affects cell-fate uncovered drug-protection by FOXO3-activation, whereas knockdown of endogenous FOXO3 increased drug-sensitivity (Figure 5).